Clinical Trial Failures Risk: KNSA's drug candidates are in various stages of clinical development, and there is no guarantee that they will demonstrate safety and efficacy required for regulatory approval. Failures in clinical trials could significantly delay or prevent product commercialization.

Regulatory Approval Hurdles Risk: Even if clinical trials are successful, KNSA's drug candidates must obtain stringent regulatory approvals from agencies like the FDA. The approval process is lengthy, unpredictable, and costly, and there is no assurance of a favorable outcome.

Capital Requirements Risk: KNSA has a history of operating losses and may require substantial additional capital to fund its research, development, and potential commercialization efforts. Inability to raise sufficient funds on acceptable terms could significantly impact its operations and future growth.